Advanced Search
Users Online: 219
Home
About us
Editorial board
Ahead of print
Current issue
Search
Archives
Submit article
Instructions
Subscribe
Contacts
Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Access statistics : Table of Contents
2009| June | Volume 4 | Issue 2
Online since
July 25, 2016
Archives
Previous Issue
Next Issue
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Viewed
PDF
Cited
REVIEW ARTICLES
Late onset rheumatoid arthritis
K Shanmuganandan, R Arunachalam
June 2009, 4(2):56-60
Late onset rheumatoid arthritis (LORA) is a distinct subset of rheumatoid arthritis with age of onset over 60. It differs from young onset disease (YORA) by a more equal sex distribution, a higher frequency of abrupt disease onset, more large joint complaints and lesser extraarticular features. Different immunogenetic associations have been described. Disease modifying drugs and low doses of prednisone are the mainstream of therapy. Biologicals are increasingly being used with better efficacy and tolerability in recent studies.
[ABSTRACT]
Full text not available
[PDF]
[Mobile Full text]
[EPub]
1,015
100
-
ORIGINAL ARTICLES
Effect of baseline rheumatoid factor (RF) levels on DAS28-response to standard DMARD-combination treatment in patients with rheumatoid arthritis (RA)
Anand N Malaviya, John B Collings, Ashima Makol, Prashant Kaushik
June 2009, 4(2):51-55
Objective:
Rheumatoid factor (RF) positivity has been associated with an unfavourable outcome in rheumatoid arthritis (RA). Our study aimed to find a baseline RF cut-off level that would determine the response to standard disease modifying anti-rheumatic drug (DMARD) combination treatment.
Patients and methods:
We studied 233 seropositive (RF levels ≥ 20 IU/mL at presentation) RA patients over a period of up to 5 years. Disease activity was assessed at each patient-encounter using disease activity score on 28 joints (DAS28). Treatment consisted of weekly methotrexate, daily hydroxychloroquine and low dose oral methlypred- nisolone as an adjunct. Sulfasalazine or leflunomide were added to the ongoing regimen if satisfactory response was not achieved by 3 months of treatment. Individual response of patients to treatment was graded using the fol- lowing DAS28 cut-off values: < 3 as low disease activity (satisfactory response), ≥ 3 as moderate and ≥ 5.1 as high (unsatisfactory response).
Results:
By analyzing all possible 2 × 2 contingency tables based on the different values of RF in the data set, using Fisher's exact test of association between RF levels and DAS28 values, a cut-off level for RF of 70 IU/mL gave the optimal discrimination between 'low' versus 'moderate or high' disease activity in the follow-up.
Conclusion:
A baseline RF cut-off value of 70 IU/mL appears to predict a 'satisfactory' versus 'unsatisfactory' response to standard DMARD-combination therapy in RA over time.
[ABSTRACT]
Full text not available
[PDF]
[Mobile Full text]
[EPub]
959
85
-
REVIEW ARTICLES
Role of nuclear medicine in evaluation and management of joint diseases
AVS Anil Kumar, PG Kumar, S Shankar
June 2009, 4(2):61-68
Nuclear medicine is a evolving speciality with a promising role in rheumatic disorders. A number of radiopharmaceu- ticals and nuclear scintigrahic procedures are available for evaluation of inflammatory and non inflammatory joint diseases. This review focuses on the current application of nuclear medicine in joint diseases.
[ABSTRACT]
Full text not available
[Mobile Full text]
[EPub]
1,018
0
-
ORIGINAL ARTICLES
Assessment of serum nitrite as biomarker of disease activity in ankylosing spondylitis
A Kumar, SK Falodia, S Shankar, R Grover, V Marwaha, R Aneja, K Srivastava, N Das
June 2009, 4(2):47-50
Background:
The assessment of disease activity in patients with ankylosing spondylitis (AS) continues to be a chal- lenging issue. The currently available markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) show poor correlation with clinical disease activity. There is a need for good biomarkers to assess disease activity. We explored serum nitrite, a stable end product of metabolism of NO, which is known to rise in inflammation, as a potential biomarker of disease activity in AS.
Objectives:
To compare the levels of serum nitrite between patients with AS and healthy controls and to correlate levels of serum nitrite with disease activity in four assessment in ankylosing spondylitis (ASAS) domains.
Methods:
Fifty patients satisfying modified New York criteria for AS were recruited for the study. Patients were assessed in the following ASAS domains: physical function (BASFI), pain (VAS, 0-100), patient global assessment (VAS, -100) and inflammation (mean of the two morning stiffness related BASDAI scores). Eighty-seven healthy controls were also included for comparison. Blood samples (12 hours fasting) were obtained and stored for serum nitrite level estimation, which was done by Ding's method. The median levels of serum nitrite were compared between the two groups. Correlation of serum nitrite levels was sought with individual domains of disease activity.
Results:
The median serum nitrite levels in patients with AS were markedly elevated as compared to those in con- trols (39 μmol/L [IQR 27-50]
vs.
4.75 μmol/L [2.53-12],
P
= 0.001 (Mann-Whitney
U
test). There was only one patient whose serum nitrite level overlapped with that of controls. Clinical assessment of disease activity (individual ASAS domains-physical function (BASFI), pain, patient global assessment and inflammation (mean of the two morning stiffness) did not show a good correlation with serum nitrite levels.
Conclusions:
Serum nitrite level was increased eight folds in patients with AS when compared with controls. Thus its measurement holds promise in differentiating between inflammatory and mechanical low back pain. However, there was no variation across a range of levels of disease activity making it unsuitable as a biomarker to monitor disease activity in AS.
[ABSTRACT]
Full text not available
[PDF]
[Mobile Full text]
[EPub]
922
83
-
EDITORIAL
Nitric oxide in ankylosing spondylitis: a new disease biomarker?
A Wanchu
June 2009, 4(2):45-46
Full text not available
[PDF]
[Mobile Full text]
[EPub]
853
90
-
PG FORUM
Rheumatology Quiz
V Arya, V Dhir
June 2009, 4(2):76-76
Full text not available
[PDF]
[Mobile Full text]
[EPub]
746
161
-
PERSPECTIVE
Sjögren's syndrome: perspectives on pathogenesis and therapy
Robert I Fox, Carla M Fox
June 2009, 4(2):69-75
Full text not available
[PDF]
[Mobile Full text]
[EPub]
809
93
-
FROM THE EDITOR’S DESK
From the Editor's desk
S Shankar
June 2009, 4(2):0-0
Full text not available
[PDF]
[Mobile Full text]
[EPub]
731
85
-
PG FORUM
What is your diagnosis?
L Duggal, N Jain, J Oberoi, A Garg
June 2009, 4(2):77-79
Full text not available
[PDF]
[Mobile Full text]
[EPub]
719
79
-
International publications of interest from India: (March-May 2009)
V Arya
June 2009, 4(2):80-81
Full text not available
[PDF]
[Mobile Full text]
[EPub]
658
82
-
CORRESPONDENCE
Correspondence
June 2009, 4(2):82-83
Full text not available
[PDF]
[Mobile Full text]
[EPub]
653
76
-
ARTICLES
RheumaPandit's View from Qutub
June 2009, 4(2):84-85
Full text not available
[PDF]
[Mobile Full text]
[EPub]
570
66
-
© Indian Journal of Rheumatology | Published by Wolters Kluwer -
Medknow
Sitemap
|
What's New
|
Feedback
|
Disclaimer
|
Privacy Notice
Online since 29
th
June, 2016